The total cost of each medication in the 12 months post-index was generally highest in the COPD cohort, although the asthma cohort had the highest total cost for anti-IgE, ICS, LTRA and ICS/LABA medications (Table 2). Here, IGHE is linked to chronic obstructive pulmonary disease.